Occurrence of leukaemia following gene therapy of X-linked SCID.
about
ZAP-70 restoration in mice by in vivo thymic electroporationA capsid-modified helper-dependent adenovirus vector containing the beta-globin locus control region displays a nonrandom integration pattern and allows stable, erythroid-specific gene expression.Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon systemGene therapy for severe combined immunodeficiency: are we there yet?Hematopoietic stem cell engineering at a crossroadsCardiovascular gene therapy for myocardial infarctionGenetics of SCIDCardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failureToxicity and management in CAR T-cell therapyIdentifying Cancer Driver Genes Using Replication-Incompetent Retroviral VectorsHighly efficient endogenous human gene correction using designed zinc-finger nucleasesIdentification of synthetic endothelial cell-specific promoters by use of a high-throughput screen.Gene specificity of suppression of transgene-mediated insertional transcriptional activation by the chicken HS4 insulator.Concise review: lessons learned from clinical trials of gene therapy in monogenic immunodeficiency diseases.Specific insertions of zinc finger domains into Gag-Pol yield engineered retroviral vectors with selective integration propertiesTranscription activator-like effector nuclease-mediated transduction of exogenous gene into IL2RG locusRecent developments in gene transfer: risk and ethics.Optimized lentiviral vector design improves titer and transgene expression of vectors containing the chicken beta-globin locus HS4 insulator element.Clinical responses to gene therapy in joints of two subjects with rheumatoid arthritis.Gene delivery to the spinal cord: comparison between lentiviral, adenoviral, and retroviral vector delivery systemsThe role of human papillomavirus 16 E6 in anchorage-independent and invasive growth of mouse tonsil epithelium.Induced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa.Efficient, high-throughput transfection of human embryonic stem cellsImproved ex vivo expansion of adult hematopoietic stem cells by overcoming CUL4-mediated degradation of HOXB4.Characterization of human T lymphocytes engineered to express interleukin-15 and herpes simplex virus-thymidine kinaseHematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome)Open questions: a logic (or lack thereof) of genome organization.Gene therapy for bone healing.Complete correction of murine Artemis immunodeficiency by lentiviral vector-mediated gene transferEnhancing Cell therapies from the Outside In: Cell Surface Engineering Using Synthetic Nanomaterials.Gene therapy for ocular diseasesTranslating gene transfer: a stalled effortRepublished review: Gene therapy for ocular diseases.Current advances in retroviral gene therapy.Novel viral vector systems for gene therapy.Leukemia cells and the cytokine network: therapeutic prospects.Targeted gene addition into a specified location in the human genome using designed zinc finger nucleases.Gene Therapy of ABCA4-Associated Diseases.Globin gene transfer as a potential treatment for the beta-thalassaemias and sickle cell disease.Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene.
P2860
Q21092215-246A12E1-AB5B-452B-B0A5-F1288609BCD6Q24530140-4069C214-B3A4-40E9-AD97-9B29A791AF00Q24631198-5DACC488-5612-4E9C-918B-AEC4E86CF074Q24680426-F8DBA80C-DEEA-4EF9-9E03-73A11452A4A5Q27001570-4168586F-071A-4160-AB9C-C0051A41AF76Q27014770-AA142EEB-3090-4097-94F8-A266EF2C1D55Q27499229-D7850D2B-C425-419E-AB29-53272B62F422Q27691424-99BA46E3-1C0E-4425-8FE1-71C967C1D785Q28075314-621948E0-5C82-4807-AB60-DBAE7A6F0D3FQ28077919-9A5FE9D3-D76B-42CB-8859-921782382D7CQ28243157-FEBA6DCE-1703-436C-8CB0-9002FA411919Q31066742-3F389CE2-F334-43DC-A978-8253E7C90B9FQ33470262-B37A2F5E-8AC1-45D4-B32A-46819D9B9D17Q33552027-E8A28B4D-0D92-4812-B0BF-58C5904442EBQ33628417-85FE8126-23C1-4935-82B2-25A64CB465ACQ33651871-2351BF60-8992-464A-AB27-9BC5E601E97AQ33709989-7B5911AA-C3A4-41D5-995F-FBDFB823D129Q33713427-44C7C3B5-09A9-43D1-9256-16D2F12E26BDQ33791993-CA2D8C38-0AA2-48B2-86F5-E0AD9FA82CC8Q33821596-F77005BD-0151-4B6A-A3C3-470589760730Q34049382-3654F63C-3F84-4FCE-ABF3-C3A3B8FFBA48Q34120479-823A4139-3EE2-46C3-AB87-41FDCEADA539Q34135224-D4003FB6-C3A3-4023-A1B7-8E5A2F969B94Q34334720-7A158FA3-5DA9-4D04-A697-95E36D2CBD15Q34338927-7FBAE1C2-7220-4388-9502-0310931B76DDQ34557967-5BF67094-0629-4BEC-B306-5F71BF4FF408Q34743079-751BABA5-EE44-4AEC-8763-A4D1259F85B5Q35117004-ED015702-7A62-4E55-A2BE-F948278D01EFQ35133845-83AA97FE-80A4-4383-A443-3AB2D9B19210Q35142623-84BF336D-2E5E-433D-AF23-6E721B81682CQ35160142-02B1DA1B-6372-4CAB-9095-A2453B1A1495Q35205807-020310AD-2B89-40F9-9EEA-45CCB996BB4FQ35210756-1013EA97-40AB-4BB1-95C6-D58E92B5947DQ35237554-BB940C8B-9FE7-4410-9766-03E72F848ABAQ35260938-03991CC4-23A4-4D30-A6A3-41B26490C96BQ35634259-66477FDF-5C5B-4D92-9E7A-41F7D23783FBQ35645641-EC625B68-69FE-4634-A01E-73D2F55724B8Q35663857-D8304D72-A7AF-40F3-B332-8E50F5784D40Q35813119-C08A7D2B-51E5-49B0-89EB-43D291DAD1EEQ35839860-DE50C1C4-97CD-4DF0-AE90-3E3A55B8B8B9
P2860
Occurrence of leukaemia following gene therapy of X-linked SCID.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Occurrence of leukaemia following gene therapy of X-linked SCID.
@ast
Occurrence of leukaemia following gene therapy of X-linked SCID.
@en
type
label
Occurrence of leukaemia following gene therapy of X-linked SCID.
@ast
Occurrence of leukaemia following gene therapy of X-linked SCID.
@en
prefLabel
Occurrence of leukaemia following gene therapy of X-linked SCID.
@ast
Occurrence of leukaemia following gene therapy of X-linked SCID.
@en
P2860
P356
P1476
Occurrence of leukaemia following gene therapy of X-linked SCID.
@en
P2093
Joseph C Glorioso
Michel Sadelain
P2860
P2888
P304
P356
10.1038/NRC1122
P407
P577
2003-07-01T00:00:00Z